Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTMT1 | Q9BV86 | 13/20 | 0.57 |
| ▸ | UGCG | Q16739 | 1/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29387425 | 0.79 | NTMT1 (0.61) | NTMT1UGCGCHRM2CHRM1CHRM3 | |
| SCHEMBL12696495 | 0.79 | NTMT1 (0.61) | NTMT1UGCGCHRM2CHRM1CHRM3 | |
| SCHEMBL19844441 | 0.79 | NTMT1 (0.61) | NTMT1UGCGCHRM2CHRM1CHRM3 | |
| SCHEMBL19844440 | 0.79 | NTMT1 (0.61) | NTMT1UGCGCHRM2CHRM1CHRM3 | |
| SCHEMBL29415411 | 0.78 | NTMT1 (0.61) | NTMT1UGCGCHRM2CHRM1CHRM3 | |
| SCHEMBL31522582 | 0.78 | NTMT1 (0.61) | NTMT1UGCGCHRM2CHRM1CHRM3 | |
| SCHEMBL16006997 | 0.76 | NTMT1 (0.66) | NTMT1UGCGCHRM2CHRM1CHRM3 | |
| SCHEMBL16006996 | 0.76 | NTMT1 (0.66) | NTMT1UGCGCHRM2CHRM1CHRM3 | |
| SCHEMBL19837255 | 0.76 | NTMT1 (0.58) | NTMT1UGCG | |
| SCHEMBL12613996 | 0.75 | NTMT1 (0.67) | NTMT1UGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4559918-A2 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2025-05-28 | — | — | EP | disclosed |
| EP-3673906-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORP (US) | 2025-05-14 | — | — | EP | disclosed |
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2025-01-23 | — | — | US | disclosed |
| US-12150938-B2 | Biomarker of polycystic kidney disease and uses thereof | GENZYME CORPORATION (US) | 2024-11-26 | — | — | US | disclosed |
| US-12060349-B2 | Glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2024-08-13 | — | — | US | disclosed |
| US-20220409595-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION | 2022-12-29 | — | — | US | disclosed |
| EP-4098654-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2022-12-07 | — | — | EP | disclosed |
| US-20220073508-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2022-03-10 | — | — | US | disclosed |
| EP-3177932-B1 | BIOMARKERS OF POLYCYSTIC KIDNEY DISEASE AND USES THEREOF | GENZYME CORP (US) | 2021-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12060349-B2 | Glucosylceramide synthase inhibitors | GBA1, GBA2, GALC | NTMT1 754/4885UGCG 8/4885CHRM2 4854/4885 |
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | NTMT1 795/4885UGCG 4/4885CHRM2 4853/4885 |
| US-12150938-B2 | Biomarker of polycystic kidney disease and uses thereof | PKD2, PKD1, KLKB1 | NTMT1 1332/4885UGCG 3455/4885CHRM2 4695/4885 |
| US-20220409595-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | NTMT1 787/4885UGCG 5/4885CHRM2 4865/4885 |
| US-20220073508-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | NTMT1 795/4885UGCG 4/4885CHRM2 4853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.